Paz-Ares L, López-Pousa A, Poveda A, Balañá C, Ciruelos E, Bellmunt J, Del Muro JG, Provencio M, Casado A, Rivera-Herrero F, Izquierdo MA, Nieto A, Tanovi? A, Cortes-Funes H, Buesa JM.
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.
Invest New Drugs. 2012 Apr;30(2):729-40.
Porta R, Sánchez-Torres JM, Paz-Ares L, Massutí B, Reguart N, Mayo C, Lianes P, Queralt C, Guillem V, Salinas P, Catot S, Isla D, Pradas A, Gúrpide A, de Castro J, Polo E, Puig T, Tarón M, Colomer R, Rosell R.
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.
Eur Respir J. 2011 Mar;37(3):624-31.
Corral J, López-Villalobos JL, Gomez-Izquierdo L, Borrego I, Paz-Ares L.
Pathologic complete responses after chemotherapy plus figitumumab in stage IV non-small-cell lung cancer.
J Clin Oncol. 2011 Mar 1;29(7):e163-5.
Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE, Paz-Ares L, Schumacher KM, Goddemeier T, O'Byrne KJ, Pirker R.
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
Lancet Oncol. 2011 Jan;12(1):30-7.
Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, Pollak MN.
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.
Br J Cancer. 2011 Jan 4;104(1):68-74.
Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Abad M, Domínguez S, Florián J, Llorca C, Méndez M, Godes M, Cubedo R, Murias A, Batista N, García MJ, Caballero R, de Alava E.
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer.
Breast Cancer Res Treat. 2010 Aug;123(1):149-57.
Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodríguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Muñoz M, López Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florián J, Li J, López García-Asenjo JA, Sáez A, Rios MJ, Almenar S, Peiró G, Lluch A; GEICAM 9805 Investigators.
Adjuvant docetaxel for high-risk, node-negative breast cancer.
N Engl J Med. 2010 Dec 2;363(23):2200-10.
Calvo E, Maroto P, del Muro XG, Climent MA, González-Larriba JL, Esteban E, López R, Paz-Ares L, Bellmunt J, Castellano D.
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations.
Cancer Metastasis Rev. 2010 Aug;29 Suppl 1:11-20.
Calvo E, Maroto P, del Muro XG, Climent MA, González-Larriba JL, Esteban E, López R, Paz-Ares L, Bellmunt J, Castellano D.
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma.
Cancer Metastasis Rev. 2010 Aug;29 Suppl 1:1-10.
Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, Manguán-García C, Cejas P, López-Ríos F, Paz-Ares L, de CastroCarpeño J, Nistal M, Belda-Iniesta C, Perona R.
IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Oncogene. 2010 Mar 18;29(11):1681-90.
Dickgreber NJ, Sorensen JB, Paz-Ares LG, Schytte TK, Latz JE, Schneck KB, Yuan Z, Sanchez-Torres JM.
Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
Clin Cancer Res. 2010 May 15;16(10):2872-80.
Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, Hixon ML, Reynolds J, McDonald S, Ang A, Rimm DL, Langer CJ, Blakely J, Garland L, Paz-Ares LG, Karp DD, Lee AV.
Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition.
Clin Cancer Res. 2010 Sep 15;16(18):4654-65.
Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R.
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71.
Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V; ESMO Guidelines Working Group.(Autor G)
Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2010 May;21 Suppl 5:v140-6.
Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R.
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
Ann Oncol. 2010 Sep;21(9):1794-803.
Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure A, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J; Spanish Society of Medical Oncology.
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).
Ann Oncol. 2010 Feb;21(2):195-8.
Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V; ESMO Guidelines Working Group.(Autor G).
Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2010 May;21 Suppl 5:v147-54.
Paz-Ares L, Soulières D, Melezínek I, Moecks J, Keil L, Mok T, Rosell R, Klughammer B.
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.
J Cell Mol Med. 2010 Jan;14(1-2):51-69.
Alba E, Ruiz-Borrego M, Margelí M, Rodríguez-Lescure A, Sánchez-Rovira P, Ruiz A, Mel-Lorenzo JR, Ramos-Vázquez M, Ribelles N, Calvo E, Casado A, Márquez A, Vicente D, García-Sáenz JA, Martín M.
Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
Breast Cancer Res Treat. 2010 Jul;122(1):169-76.
Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Abad M, Domínguez S, Florián J, Llorca C, Méndez M, Godes M, Cubedo R, Murias A, Batista N, García MJ, Caballero R, de Alava E.
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer.
Breast Cancer Res Treat. 2010 Aug;123(1):149-57.
Agulló-Ortuño MT, López-Ríos F, Paz-Ares L.
Lung cancer genomic signatures.
J Thorac Oncol. 2010 Oct;5(10):1673-91.
Novello S, Pimentel FL, Douillard JY, O'Brien M, von Pawel J, Eckardt J, Liepa AM, Simms L, Visseren-Grul C, Paz-Ares L.
Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer.
J Thorac Oncol. 2010 Oct;5(10):1602-8.
Conde E, Angulo B, Redondo P, Toldos O, García-García E, Suárez-Gauthier A, Rubio-Viqueira B, Marrón C, García-Luján R, Sánchez-Céspedes M, López-Encuentra A, Paz-Ares L, López-Ríos F.
The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung.
PLoS One. 2010 Aug 17;5(8):e12209.
Muñoz M, Pavón A, Rosso M, Salinas MV, Pérez A, Carranza A, González-Ortega A.
Immunolocalization of NK-1 receptor and Substance P in human normal placenta.
Placenta. 2010 Jul;31(7):649-51.
Paz-Ares LG, Altug S, Vaury AT, Jaime JC, Russo F, Visseren-Grul C.
Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advan
BMC Cancer. 2010 Mar 8;10:85.
Baudin E, Droz JP, Paz-Ares L, van Oosterom AT, Cullell-Young M, Schlumberger M.
Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma.
Am J Clin Oncol. 2010 Feb;33(1):83-8.
Paz-Ares L, del Muro JG, Grande E, Díaz S.
A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.
J Clin Pharm Ther. 2010 Aug;35(4):429-38.
González-Pérez LM, Pérez-Ceballos JL, Carranza-Carranza A.
Mandibular intraosseous lipoma: clinical features of a condylar location.
Int J Oral Maxillofac Surg. 2010 Jun;39(6):617-20.
García-Carbonero R, Gómez España MA, Casado Sáenz E, Alonso Orduña V, Cervantes Ruipérez A, Gallego Plazas J, García Alfonso P, Juez Martel I, González Flores E, Lomas Garrido M, Isla Casado D.
SEOM clinical guidelines for the treatment of advanced colorectal cancer.
Clin Transl Oncol. 2010 Nov;12(11):729-34.
López-Calderero I, Sánchez Chávez E, García-Carbonero R.
The insulin-like growth factor pathway as a target for cancer therapy.
Clin Transl Oncol. 2010 May;12(5):326-38.
Durán I, García-Velasco A, Ballestín C, García E, Martínez-Tello F, Pond GR, García-Carbonero R, Cortés-Funés H, Paz-Ares L.
Expression of EGFR, HER-2/neu and KIT in germ cell tumours.
Clin Transl Oncol. 2010 Jun;12(6):443-9.
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M,
Screening for epidermal growth factor receptor mutations in lung cancer.
The New England journal of medicine 2009 Sep;361(10):958-67
Martín-Algarra S, Espinosa E, Rubió J, López López JJ, Manzano JL, Carrión LA, Plazaola A, Tanovic A, Paz-Ares L
Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma.
European journal of cancer (Oxford, England : 1990) 2009 Mar;45(5):732-5
Molina-Pinelo S, Vallejo A, Díaz L, Soriano-Sarabia N, Ferrando-Martínez S, Resino S, Muñoz-Fernández MA, Leal M
Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.
The Journal of antimicrobial chemotherapy 2009 Sep;64(3):579-88
Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009 Nov;4(11):1397-403
de Felipe B, Leal M, Soriano-Sarabia N, Gutiérrez A, López-Cortés L, Molina-Pinelo S, Vallejo A
HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse.
Journal of viral hepatitis 2009 Jan;16(1):21-7
Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May;27(15):2516-22
Schöffski P, Guillem V, Garcia M, Rivera F, Tabernero J, Cullell M, Lopez-Martin JA, Pollard P, Dumez H, del Muro XG, Paz-Ares L
Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.
Marine drugs 2009 ;7(1):57-70
Moreno Nogueira JA, Ruiz Borrego M, Pérez Valderrama B, Valero Azbiru M
[Treatment of aggressive non-Hodgkin's lymphomas]
Revista clínica española 2009 Feb;209(2):88-92
Paz-Ares L, Ross H, O'Brien M, Riviere A, Gatzemeier U, Von Pawel J, Kaukel E, Freitag L, Digel W, Bischoff H, García-Campelo R, Iannotti N, Reiterer P, Bover I, Prendiville J, Eisenfeld AJ, Oldham FB, Bandstra B, Singer JW, Bonomi P
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer.
British journal of cancer 2008 May;98(10):1608-13
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Ares LP, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.
European urology 2008 Mar;53(3):478-96
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz-Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.
European urology 2008 Mar;53(3):497-513
Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, García M, Salazar R, López A, Blanco M, Nieto A, Jimeno J, Izquierdo MA, Trigo JM
Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Feb;14(4):1116-23
Alvarez-Cabellos R, Garcia-Carbonero R, Garcia-Lacalle C, Gomez P, Tercero A, Sanchez D, Paz-Ares L
Fluorouracil-based chemotherapy in patients with gastrointestinal malignancies: influence of nutritional folate status on toxicity.
Journal of chemotherapy (Florence, Italy) 2007 Dec;19(6):744-9
Folprecht G, Tabernero J, Köhne CH, Zacharchuk C, Paz-Ares L, Rojo F, Quinn S, Casado E, Salazar R, Abbas R, Lejeune C, Marimón I, Andreu J, Ubbelohde U, Cortes-Funes H, Baselga J.
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
Clin Cancer Res. 2008; 14:215-23.
López-Martin A, Ballestín C, Garcia-Carbonero R, Castaño A, Lopez-Ríos F, López-Encuentra A, Sánchez-Cespedes M, Castellano D, Bartolomé A, Cortés-Funes H, Paz-Ares L
Prognostic value of KIT expression in small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2007 Jun;56(3):405-13
Rosell R, Taron M, Sanchez JJ, Paz-Ares L
Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors.
Future oncology (London, England) 2007 Jun;3(3):277-83
Paz-Ares L, Rivera-Herreros F, Díaz-Rubio E, García M, Casado E, Cubedo R, Gravalos C, Alfaro V, Gómez J, Izquierdo MA, Tabernero J
Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.
Clinical colorectal cancer 2007 May;6(7):522-8
Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Jul;25(19):2747-54
Rosell R, Felip E, Paz-Ares L
How could pharmacogenomics help improve patient survival?
Lung cancer (Amsterdam, Netherlands) 2007 Aug;57 Suppl 2():S35-41
Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, Baselga J,
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007 Mar;18(3):522-8
L Paz-Ares, R García-Carbonero
Management of Medical Emergencias.
En F Cavalli, SB Kaye, MJ Piccard, JO Armitage & HH Hansen (Eds). Textbook of Medical Oncology (4th edition). Martin Dunitz LTD, 2009 (en imprenta).
J Sepúlveda, MJ Echarri, L Paz-Ares.
Factores de Crecimiento Hematopoyético.
En: “Oncología Médica” (2ª edicción), H Cortes-Funes, R Colomer (eds.). Editorial Nova Sidonia (2008).
I Diaz-Padilla, L Paz-Ares.
Inhibidores de tirosina kinasa.
En: “Oncología Médica” (2ª edicción). H Cortes-Funes, R Colomer (eds.), Editorial Nova Sidonia (2008)
L Paz-Ares
Introducción
“Tumores de Origen desconocido” L Paz-Ares (ed.), You and Us (2007) pp. 4-7.
Paz-Ares L, Carnero A.
Between bench and bed side: PI3K inhibitors.
Curr Mol Pharmacol. 2010 Jun;3(2):79-90.
